Breast cancer is a global cause for concern owing to its high incidence around the world.
The alarming increase in breast cancer cases emphasizes the management of disease at …

Breast cancer is a heterogeneous disease and differs greatly among different patients
(intertumor heterogeneity) and even within each individual tumor (intratumor heterogeneity) …

Purpose To update the ASCO clinical practice guideline on adjuvant endocrine therapy
based on emerging data about the optimal duration of aromatase inhibitor (AI) treatment …

Background The administration of endocrine therapy for 5 years substantially reduces
recurrence rates during and after treatment in women with early-stage, estrogen-receptor …

ABSTRACT The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna,
Austria reviewed substantial new evidence on loco-regional and systemic therapies for early …

In 2012, the estimated age-adjusted annual incidence of breast cancer in 40 European
countries was 94.2/100 000 and the mortality 23.1/100 000 [1]. The incidence increased …

ABSTRACT The 14th St Gallen International Breast Cancer Conference (2015) reviewed
substantial new evidence on locoregional and systemic therapies for early breast cancer …

Purpose To provide recommendations on appropriate use of breast tumor biomarker assay
results to guide decisions on adjuvant systemic therapy for women with early-stage invasive …

Biomarkers play an essential role in the management of patients with invasive breast
cancer. For selecting patients likely to respond to endocrine therapy, both oestrogen …

Importance Multiple molecular signatures are available for managing estrogen receptor (ER)–
positive breast cancer but with little direct comparative information to guide the patient's …